Close Menu

NEW YORK – The GenomeWeb Index rose nearly 15 percent in the first half of 2020, largely on the strength of companies that developed diagnostic tests for SARS-Cov-2 who have seen their stocks surge during the pandemic.

The index outperformed the Dow Jones Industrial Average, the Nasdaq, and the Nasdaq Biotechnology Index, which fell nearly 10 percent, rose 12 percent, and rose nearly 14 percent, respectively, in H1 2020. Individual stock performances in the GenomeWeb Index were largely positive in H1, as 25 of the 32 stocks saw gains and only seven saw losses.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.

Noel Rose, the "father of autoimmunity," has died at 92, the Washington Post reports.

According to CNN, Legionella was discovered in buildings leased by the Centers for Disease Control and Prevention as they reopened following coronavirus pandemic-related closures.

In PLOS this week: genetic analysis of malaria parasite populations in Southeast Asia, genomic surveillance of yellow fever virus in São Paulo, and more.